ACTION

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Rite Aid Securities Litigation

Retrieved on: 
Monday, November 20, 2023

IF YOU PURCHASED OR ACQUIRED RITE AID CORPORATION (“RITE AID”) COMMON STOCK BETWEEN OCTOBER 20, 2016 AND JUNE 28, 2017, INCLUSIVE (THE “CLASS”), YOU COULD RECEIVE A PAYMENT FROM A CLASS ACTION SETTLEMENT.

Key Points: 
  • IF YOU PURCHASED OR ACQUIRED RITE AID CORPORATION (“RITE AID”) COMMON STOCK BETWEEN OCTOBER 20, 2016 AND JUNE 28, 2017, INCLUSIVE (THE “CLASS”), YOU COULD RECEIVE A PAYMENT FROM A CLASS ACTION SETTLEMENT.
  • CERTAIN PERSONS ARE EXCLUDED FROM THE DEFINITION OF THE CLASS AS SET FORTH IN THE STIPULATION OF SETTLEMENT.
  • YOUR RIGHTS MAY BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • If you previously excluded yourself from the Class, you will have no right to recover money pursuant to the Settlement.

Alpha Motor Corporation Receives Patent Allowance for WOLF Electric Truck, Introduces ACTION SERIES

Retrieved on: 
Thursday, December 14, 2023

IRVINE, Calif., Dec. 14, 2023 /PRNewswire/ -- Alpha Motor Corporation (Alpha) is pleased to introduce the ACTION SERIES Special Edition WOLF Electric Truck , marking a significant milestone with the recent patent allowance.

Key Points: 
  • IRVINE, Calif., Dec. 14, 2023 /PRNewswire/ -- Alpha Motor Corporation (Alpha) is pleased to introduce the ACTION SERIES Special Edition WOLF Electric Truck , marking a significant milestone with the recent patent allowance.
  • Following the successful validation of the WOLF truck's driving performance, Alpha is increasing the production of test vehicles.
  • "We're bringing imagination back into the equation of owning an electric vehicle," said Alpha Motor Corporation.
  • The ACTION SERIES WOLF Electric Truck highlights its modular design, enabling customization to cater to various consumer needs.

Hagens Berman Sobol Shapiro LLP Announce a Class Action Which May Affect You If You Had A Health Plan That Paid for Generic Prescription Drugs Purchased at CVS Pharmacy

Retrieved on: 
Friday, November 10, 2023

prescription drugs purchased at CVS Pharmacy, a

Key Points: 
  • prescription drugs purchased at CVS Pharmacy, a
    class action lawsuit could affect your rights.
  • A CLASS ACTION LAWSUIT is pending in the U.S. District Court for the District of Rhode Island (the "Court").
  • Class Plaintiffs contend that they were overcharged for the generic drugs in the HSP program as a result of Defendants' actions.
  • The complete class definitions are available in the LONG-FORM NOTICE on the website www.CVSHSPClassAction.com or by contacting the Notice Administrator.

Notice of Written Resolution

Retrieved on: 
Tuesday, November 7, 2023

The Issuer today announces the circulation of a notice of written resolution (the “Notice of Written Resolution”) requesting that holders of the Notes (the “Noteholders”) consider the extraordinary resolution set out in the Notice of Written Resolution being proposed as a written resolution, which contains the proposal by the Issuer for Noteholders to consent to amendments to the trust deed dated 17 September 2019 between Metro Bank PLC (“Metro Bank”) and The Law Debenture Trust Corporation p.l.c.

Key Points: 
  • The Issuer today announces the circulation of a notice of written resolution (the “Notice of Written Resolution”) requesting that holders of the Notes (the “Noteholders”) consider the extraordinary resolution set out in the Notice of Written Resolution being proposed as a written resolution, which contains the proposal by the Issuer for Noteholders to consent to amendments to the trust deed dated 17 September 2019 between Metro Bank PLC (“Metro Bank”) and The Law Debenture Trust Corporation p.l.c.
  • (the “Trustee”), as supplemented by a supplemental trust deed dated 19 May 2023 between the Issuer, the Trustee and Metro Bank (together, the “Trust Deed”), by way of a second supplemental trust deed to modify, upon prior satisfaction of the Effectiveness Conditions (as defined in the Notice of Written Resolution) and with effect on and from the Settlement Date (as defined in the Notice of Written Resolution and currently expected to be 30 November 2023), Condition 10(a) of the terms and conditions of the Notes such that the maturity date of the Notes will be the Settlement Date and the redemption of the Notes will be effected by way of delivery, to the holders thereof, of (i) the £1,000 in principal amount of the New MREL Notes (as defined in the Notice of Written Resolution) to be issued by the Issuer for each £1,000 in principal amount of Notes held by each such Noteholder and (ii) the Accrued Interest Amount (as defined in the Notice of Written Resolution) in cash, as well as consequential or related amendments to the Trust Deed (as more fully described in the Notice of Written Resolution, the “Proposal”).
  • Noteholders are urged to read the Notice of Written Resolution carefully, together with any other publicly available information on the Issuer and its group which such Noteholder shall deem necessary, before submitting a Voting Instruction in connection with the Written Resolution (each as defined in the Notice of Written Resolution).
  • Any questions relating to this Announcement or the Notice of Written Resolution should be addressed to the Tabulation Agent as follows:

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, November 2, 2023

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update.
  • Chimerix reported a net loss of $24.0 million, or $0.27 per basic and diluted share, for the third quarter of 2023.
  • Research and development expenses increased to $17.4 million for the third quarter of 2023, compared to $15.3 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss third quarter 2023 financial results and provide a business update today at 8:30 a.m.

SXSW EDU® Emphasizes Pedagogy and the Power of Community in 2024 Programming Lineup

Retrieved on: 
Wednesday, October 25, 2023

AUSTIN, Texas, Oct. 25, 2023 /PRNewswire/ -- Today, SXSW EDU® announced the majority of the conversations, panels, and workshops making up its 2024 Conference & Festival. The renowned education convening, held from March 4-7, 2024, will feature 208 sessions and counting, all selected through the community-driven PanelPicker® process. With a heavy focus on tracks such as Teaching & Learning and Equity & Justice, accepted programming will cover topics ranging from utilizing AI to help teachers simulate success to navigating post-SCOTUS affirmative action.

Key Points: 
  • The renowned education convening, held from March 4-7, 2024, will feature 208 sessions and counting, all selected through the community-driven PanelPicker® process.
  • The top five overarching tracks hosting the most approved content include Teaching & Learning, Equity & Justice, Leadership for Tomorrow, Health & Wellbeing, and Community Initiatives.
  • "The PanelPicker process illuminates the most relevant topics and issues that matter to SXSW EDU's global community.
  • (Work Reimagined)
    Juanita Soranno, Vice President, Global Social Impact & Innovation, edX
    To learn more about the exciting 2024 program, please visit sxswedu.com/ schedule .

Pomerantz LLP and Levi & Korsinsky LLP Announce Notice of Proposed Settlement If You Purchased or Otherwise Acquired Common Stock Of Bakkt Holdings, Inc. ("Bakkt") or VPC Impact Acquisition Holdings ("VIH"), or Warrants To Purchase Bakkt or VIH Common Sto

Retrieved on: 
Monday, October 16, 2023

CERTAIN PERSONS ARE EXCLUDED FROM THE DEFINITION OF THE SETTLEMENT CLASS AS SET FORTH IN THE STIPULATION AND AGREEMENT OF SETTLEMENT.

Key Points: 
  • CERTAIN PERSONS ARE EXCLUDED FROM THE DEFINITION OF THE SETTLEMENT CLASS AS SET FORTH IN THE STIPULATION AND AGREEMENT OF SETTLEMENT.
  • YOUR RIGHTS MAY BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • § 78u-4(a)(4) in connection with their representation of the Settlement Class and, if so, in what amount.
  • If you submit a written request for exclusion, you will have no right to recover money pursuant to the Settlement.

The America Project Proudly Sponsors A Concert for Liberty Benefit for Doc Pete Chambers and The A-TEAM Join us!

Retrieved on: 
Tuesday, October 10, 2023

A letter from Doc Chambers:

Key Points: 
  • A letter from Doc Chambers:
    This event is being held to support ACTION on the border.
  • NOT some self aggrandizing, "patting on the back" event, nor paid speakers brought into some grand venue to rub elbows with famous people.
  • This is a "WE THE PEOPLE" run operation to continue support for the plain folks on the border protecting everything that is dear to the American character.
  • I opted to hold it at a venue representing the service men and women who have fought in foreign wars.

Monteverde & Associates PC and Kahn Swick & Foti Announce Proposed Class Action Settlement on Behalf of Holders of GW Pharmaceuticals PLC American Depositary Shares

Retrieved on: 
Saturday, September 16, 2023

TO: RECORD AND BENEFICIAL HOLDERS OF GW PHARMACEUTICALS, PLC.

Key Points: 
  • TO: RECORD AND BENEFICIAL HOLDERS OF GW PHARMACEUTICALS, PLC.
  • THE PARTIES TO A SHAREHOLDER CLASS ACTION SUIT CONCERNING THE MERGER HAVE AGREED TO A PROPOSED SETTLEMENT.
  • Settlement Class Members should check the Settlement Class website in advance of the Final Approval Hearing to determine whether that hearing instead will occur via a remote link.
  • All Members of the Settlement Class who do not timely and validly request exclusion from the Settlement Class will be bound by any judgment entered in the Litigation pursuant to the Stipulation of Settlement.

Hyperfine, Inc. Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023

Gross margin for the second quarter of 2023 was $1.44 million, compared to $(0.17) million in the second quarter of 2022.

Key Points: 
  • Gross margin for the second quarter of 2023 was $1.44 million, compared to $(0.17) million in the second quarter of 2022.
  • Research and development expenses for the second quarter of 2023 were $5.33 million, compared to $7.27 million in the second quarter of 2022.
  • Sales, general, and administrative expenses for the second quarter of 2023 were $7.81 million, compared to $15.76 million in the second quarter of 2022.
  • ET on Monday, August 14, 2023, to discuss its second quarter 2023 financial results and provide a business update.